Across TCGA pan-cancer cohorts, SEMA4B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SEMA4B data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SEMA4B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SEMA4B expression acts as an unfavorable survival marker.

LUAD, CCRCC, and PDAC are the cancer types where SEMA4B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.473	0.769	<.001	67	view →
CCRCC	DFS	Quartile	II,III,IV	0.323	0.811	<.001	47	view →
PDAC	DFS	Median	All	0.691	0.831	.005	28	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SEMA4B tumor-vs-normal RNA expression · all SEMA4B data types